| HOME >> BIOLOGY >> TECHNOLOGY |
2008 Financial Outlook
The Company is reiterating its adjusted earnings per fully diluted share guidance for 2008 to be in the range of approximately $2.75 - $3.05. The Company expects total revenues for 2008 to be in the range of $2.7 - $2.8 billion, including total product sales in the range of $2.5 - $2.6 billion. On the expense side for 2008, the Company expects investment in R&D to be approximately $285 - $290 million, and SG&A expenses to be approximately $810 - $830 million.
The Company's adjusted earnings guidance for 2008 excludes: the impact of amortization costs associated with acquired products; contributions and/or losses from the DDD&I operations that the Company plans to divest; incremental depreciation related to purchase accounting; the impact of any unscheduled launches resulting from patent challenges; other business development activities; refinancing activities that may be completed after the date hereof and on or before December 31, 2008; and, expenses incurred resulting from the proposed acquisition of Barr by Teva.
Conference Call/Webcast
The Company will host a Conference Call at 8:30 AM Eastern time on Thursday, August 7, 2008 to discuss earnings results for the quarter ended June 30, 2008. The number to call from within the United States is (800) 230- 1059 and (612) 332-0107 Internationally. A replay of the conference call will be available from 10:30 AM Eastern time on August 7, 2008 through 11:59 PM Eastern time August 21, 2008 and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 930193.
The Conference Call will also be Webcast live on the Internet.
Investors and other interested parties may access the live webcast through
th
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |